Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets
Kunihiko Araki, … , Gen Sobue, Masahisa Katsuno
Kunihiko Araki, … , Gen Sobue, Masahisa Katsuno
Published July 29, 2019
Citation Information: J Clin Invest. 2019;129(9):3578-3593. https://doi.org/10.1172/JCI124481.
View: Text | PDF
Research Article Metabolism Neuroscience

TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets

  • Text
  • PDF
Abstract

TAR DNA-binding protein 43 kDa (TDP-43), encoded by TARDBP, is an RNA-binding protein, the nuclear depletion of which is the histopathological hallmark of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder affecting both upper and lower motor neurons. Besides motor symptoms, patients with ALS often develop nonneuronal signs including glucose intolerance, but the underlying pathomechanism is still controversial, i.e., whether it is impaired insulin secretion and/or insulin resistance. Here, we showed that ALS subjects reduced early-phase insulin secretion and that the nuclear localization of TDP-43 was lost in the islets of autopsied ALS pancreas. Loss of TDP-43 inhibited exocytosis by downregulating CaV1.2 calcium channels, thereby reducing early-phase insulin secretion in a cultured β cell line (MIN6) and β cell–specific Tardbp–knockout mice. Overexpression of CaV1.2 restored early-phase insulin secretion in Tardbp–knocked-down MIN6 cells. Our findings suggest that TDP-43 regulates cellular exocytosis mediated by L-type voltage–dependent calcium channels and, thus, plays an important role in the early phase of insulin secretion by pancreatic islets. Thus, nuclear loss of TDP-43 is implicated in not only the selective loss of motor neurons, but also in glucose intolerance due to impaired insulin secretion at an early stage of ALS.

Authors

Kunihiko Araki, Amane Araki, Daiyu Honda, Takako Izumoto, Atsushi Hashizume, Yasuhiro Hijikata, Shinichiro Yamada, Yohei Iguchi, Akitoshi Hara, Kazuhiro Ikumi, Kaori Kawai, Shinsuke Ishigaki, Yoko Nakamichi, Shin Tsunekawa, Yusuke Seino, Akiko Yamamoto, Yasunori Takayama, Shihomi Hidaka, Makoto Tominaga, Mica Ohara-Imaizumi, Atsushi Suzuki, Hiroshi Ishiguro, Atsushi Enomoto, Mari Yoshida, Hiroshi Arima, Shin-ichi Muramatsu, Gen Sobue, Masahisa Katsuno

×

Figure 2

Endogenous TDP-43 depletion suppresses the first phase of insulin secretion in MIN6 cells.

Options: View larger image (or click on image) Download as PowerPoint
Endogenous TDP-43 depletion suppresses the first phase of insulin secret...
(A) mRNA expression levels of Tardbp, encoding TDP-43 (control siRNA, Control; Tardbp siRNA, T1 or T2) (n = 7 each, 1-way ANOVA). (B) Immunoblotting of MIN6 cells transfected with control, T1, or T2 (control, n = 10; T1, n = 5; T2, n = 7, 1-way ANOVA). (C) The insulin assay with low (2.8 mmol/L) and high glucose (16.7 mmol/L) (control, n = 12; T1, n = 12; T2, n = 7, 1-way ANOVA). (D) TDP-43 rescue experiments with mock plasmid or a siRNA-resistant form of murine TDP-43 (mut-mTDP) (n = 6 each, 1-way ANOVA). (E) The insulin assay with low and high glucose. mut-mTDP-43 recovered the glucose-induced insulin secretion (n = 8 each, 1-way ANOVA). (F) T1 siRNA against Tardbp effectively reduced the protein level of TDP-43 (green). Scale bars: 5 μm. (G and H) Histogram showing the number of fusion events from GFP-tagged granules in control siRNA (G) and T1 siRNA–treated MIN6 cells (H) (per 200 μm2) at 1-minute intervals after glucose stimulation and measured by TIRF microscopy (control, n = 11 cells; T1, n = 15 cells, unpaired t test). (I) Quantitative analysis of the total number of exocytotic events detected during the first phase (0–7 minutes) or second phase (>7 minutes). (J) TIRF imaging of insulin granules morphologically docked to the plasma membrane. Scale bar: 10 μm. (K) Number of docked insulin granules (per 200 μm2, control, n = 20; T1, n = 23 cells, unpaired t test). (L) The insulin assay with low glucose, high glucose, and KCL stimulation (n = 8 each, 1-way ANOVA). Values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts